Peter Jackson Invests Millions to 'De-Extinct' This Species
The Associated Press reported earlier this week that Jackson and his partner, Fran Walsh, have invested $15 million in a joint effort with bioscience company Colossal and the Ngāi Tahu Research Centre in New Zealand to bring the South Island giant moa back from extinction. The moa, known as moa nunui by the Māori, was the tallest species of bird on record to ever have walked on Earth and was one of the tallest, surpassed only by the Malagasy elephant bird. They existed for about 4,000 years and went extinct roughly 600 years ago.
Jackson, an avid collector of moa bones, got in touch with Colossal after hearing about the company's efforts to 'de-extinct' the dire wolf and the woolly mammoth. 'The movies are my day job, and the moa are my fun thing I do,' he said. 'Every New Zealand schoolchild has a fascination with the moa.'Although scientists say it is 'unlikely' that the moa could be completely brought back from extinction, it's possible that its traits could be infused into other bird species. 'There's lots of different scientific hurdles that need to be overcome with any species that we pick as a candidate for de-extinction,' explained Beth Shapiro, Colossal's chief scientist. 'We are in the very early stages.'
For his part, Jackson seems to be all in. Although the director specified he's 'certainly not retired' from filmmaking during a recent interview with Screen Rant, he finds the moa consuming more of his imagination these days. 'To me, de-extincting the Moa would be just as exciting, if not more exciting, than any film I could possibly make,' Jackson admitted. 'I've made a lot of movies, but to see the giant moa brought back would be a level of excitement that I think would supersede anything at this point in time.'
Peter Jackson Invests Millions to 'De-Extinct' This Species first appeared on Men's Journal on Jul 11, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
The Dire Wolf Company's Next Target? A Giant Flightless Bird
It has taken no end of imagination for Sir Peter Jackson, the Academy Award winning—and, not incidentally, knighted—director of the Lord of the Rings and Hobbit films, to produce his entire body of cinematic work. It's a quality Jackson has had since he was a small child, when he would conjure up visions of the future. 'When I was a kid [I dreamed of] personal jet packs and flying cars and things,' Jackson said in a recent conversation with TIME. 'One of those other things I always dreamed of was to be able to bring back extinct species.' No-go on the jet packs and the flying cars. But the business of de-extinction? That's very much happening. In April, the Dallas-based biotech company Colossal Biosciences announced that it had successfully brought back the dire wolf, an animal whose howl had not been heard on Earth since the last member of the species vanished more than 10,000 years ago. Three young dire wolves currently live on a 2,000-acre preserve in an undisclosed location to protect them from the media and curiosity-seekers, and Colossal aims to produce more of the animals, with the ultimate goal of perhaps rewilding the species. Read more: The Return of the Dire Wolf The company is not stopping there. Colossal also wants to bring back the dodo, the woolly mammoth, the Tasmanian tiger—or thylacine—and more. The goal is both to increase genetic diversity and to hone genetic editing techniques to fortify existing but threatened species. Now, Colossal has announced one more species to add to its growing menagerie: the emu-like moa, a giant flightless bird that stood up to 12 ft. (3.6 m) tall, tipped the scales at more than 500 lbs (230 kg), and once ranged across New Zealand, before it was hunted to extinction by humans about 600 years ago. Like the moa, Jackson is a native New Zealander; 'I am a very proud kiwi,' he says. He is also a Colossal investor and acted as intermediary and facilitator bringing the company into partnership on the moa project with the Ngāi Tahu Research Center, a group that was founded in 2011 to foster intellectual development and conduct scientific studies for and by the Ngāi Tahu tribe of the Indigenous Māori people. 'Some of those iconic species that feature in our tribal mythology, our storytelling, are very near and dear to us,' says Ngāi Tahu archaeologist Kyle Davis, who is working on the moa de-extinction project. 'Participation in scientific research, species management, and conservation has been a large part of our activities.' 'This is completely a Māori initiative,' adds Ben Lamm, CEO and co-founder of Colossal. 'We feel like the Colossal team is an extension of the research center and the Māori.' Bringing back the moa would have implications not only for the species itself but for the environment it once inhabited and could again. The bird was what is known as a cornerstone species, one whose grazing and browsing helped prune and shape the jungle flora. Moas were also prolific dispersers of seeds from the plants they ate. The loss of the species not only eliminated that forest-restoring function, but also led to the related extinction of the Haast's eagle, which relied almost exclusively on the moa as prey. Restoring the moa would not bring the eagle back but could help at least partly restore the primal New Zealand woodlands. Bringing back the moa is of a piece with Colossal's other work, which seeks not only to restore vanished species, but to prevent related ones from slipping over the event horizon of extinction. Genetic engineering mastered in the dire wolf project, for example, is being used to edit greater diversity into the genome of the endangered red wolf. Knowledge gained in the effort to bring back the thylacine could similarly help preserve the related northern quoll. 'There are some species of birds on the South Island of New Zealand that are endangered due to the fact that they have reduced gene pools,' says Paul Scofield, senior curator of natural history at Canterbury Museum, author of 20 papers on the moa genome, and one of the scientists working on the de-extinction project. 'Some of the technology that Colossal is working with is very applicable to them.' Read more: Scientists Have Bred Woolly Mice on Their Journey to Bring Back the Mammoth That technology is decidedly challenging. De-extincting the dire wolf involved sequencing ancient DNA collected from fossil specimens and then rewriting the genome of cells from a gray wolf to resemble the extinct species with the lost ancient genes. The edited nucleus was then inserted into a domestic dog ovum whose own nucleus had been removed. That ovum was allowed to develop into an embryo in the lab and then implanted into the womb of a surrogate domestic dog, which carried the dire wolf pup to term.' Bringing back the extinct moa is harder since the incubating will be done outside the body, inside an egg. The first step in this work once again calls for sequencing the genome of the extinct target species and once again turning to a closely related living species—either the tinamou or the emu—for help. Colossal scientists will extract primordial germ cells—or cells that develop into egg and sperm—from a tinamou or emu embryo and rewrite their genome to match key features of the moa. Those edited cells will then be introduced into another embryonic tinamou or emu inside an egg. If all goes to plan, the cells will travel to the embryo's gonads, transforming them so that the females produce eggs and the males produce sperm not of the host species but of the moa. The result will be an emu or tinamou that hatches, grows up, mates, and produces eggs containing moa chicks. 'We've had some pretty big successes so far,' says Lamm. 'We have a breeding colony of tinamous but not emus, but have access to emu eggs through the many breeders out there." None of this means that the work is remotely done. Lamm concedes it could be up to ten years before a moa once again walks New Zealand—though it could come sooner. 'I'd rather underpromise and overdeliver,' he says. For now, Colossal and the Ngāi Tahu Research Center are still working to sequence the moa genome, and to do that they have to get their hands on more DNA samples. Museum specimens of moa remains satisfy some of that demand, but DNA degrades significantly over the centuries and what can't be harvested from private collections has to be dug up in field excavations—with a special eye to long, DNA-rich moa bones like the femur and tibia. 'There are a couple of really significant fossil sites, particularly one in North Canterbury, about an hour north of Christchurch,' says Scofield. 'So far we've sampled more than 60 individuals.' If those don't prove sufficient, he adds, 'we will have to go out and dig some more holes.' None of this comes cheap, and while Lamm does not disclose the exact funding for the moa de-extinction project, he does say it is an eight-figure sum. 'I saw the new Jurassic World movie and someone in it says it costs $72 million to bring back one animal,' he says. 'I was like, 'That's probably accurate.'' That up-front expenditure could pay off handsomely down the line, boosting ecotourism to New Zealand and benefiting Colossal's basic research, which is already showing for-profit potential. So far, Colossal has spun off two new companies: One, called Breaking, uses engineered microbes and enzymes to break down plastic waste. The other, Form Bio, provides AI and computational biology platforms for drug development. But it's the intangibles—the wonder of midwifing a long-extinct species back to the global family of extant ones—that is Colossal's and the Māori's most transcendent work. 'This has an excitement value to it that movies don't have,' says Jackson. 'When I see a living moa for the first time I'm going to be absolutely amazed beyond anything I've ever felt.' Write to Jeffrey Kluger at
Yahoo
18 hours ago
- Yahoo
Quitting the quit-aid: people trying to stop vaping nicotine need more support – here are some strategies to help
New Zealand is among a number of countries that encourage vaping (the use of e-cigarettes) as a tool to help people stop smoking tobacco. But what happens when people want to quit vaping? Nicotine vapes can be addictive. While they have helped many New Zealanders quit smoking cigarettes, others – including people who never smoked – now find themselves wanting to quit vaping. To better understand how and why people try to quit, we surveyed more than 1,000 people in Aotearoa New Zealand who have used nicotine vapes. The findings from our study point to a need for support that treats vaping cessation like quitting smoking because for many, the challenges are similar. We focused on New Zealanders aged 16 and over who had vaped nicotine. Of the 1,119 respondents, 401 currently vaped and 718 had quit vaping. Around one in eight had never smoked tobacco at all. We found using vapes for more than two years and with nicotine concentrations above 3% was linked to higher dependence on vaping. Most current or past vapers wanted to stop, and more than three-quarters of participants had made up to three serious attempts to quit vaping. Some people wanted to quit vaping because what began as a tool to support quitting smoking has become a new source of frustration or worry. The most common reasons to stop vaping were concerns about current or future health, disliking the feeling of being dependent, and the cost of vaping products. These motivations echo the reasons many people cite for quitting smoking, suggesting that people who vape (like most people who smoke) do not want to remain hooked on nicotine, even if it helped them quit cigarettes. Participants used a variety of strategies to quit, including abrupt cessation ('cold turkey'), switching to other forms of reduced-harm nicotine (such as nicotine patches, gums, lozenges, mouth sprays), and tapering down nicotine levels. Many also relied on support from whānau (family) and friends. These strategies mirror those used in smoking cessation. Our participants reiterate the importance of personal strategies, building on previous work on interventions that target vaping cessation. Some people did quit vaping and had no problem quitting. However, others struggled. Triggers that cause a relapse to vaping are similar to those many people who smoke experience, including stress and symptoms of nicotine withdrawal. Being around others who vape is also a trigger for relapse. These factors highlight the social and psychological effects of vaping, just as they have long been recognised in tobacco addiction research. Importantly, these triggers appeared consistent across different groups regardless of age, gender, cultural background or smoking history. Whether someone vaped to stop smoking or whether vaping was the first nicotine product they tried, quitting came with similar challenges. Our study suggests many New Zealanders are now trying to quit nicotine vapes, and some face real barriers to doing so. We think existing smoking-cessation support and medications could play a useful role. These tools include behavioural support, such as building self-belief in the ability to quit, identifying key triggers (and strategies to avoid them), stress management strategies, and access to tapering schedules (cutting down the frequency of vaping over time or gradually reducing nicotine concentration). As previous work shows, the type of support needed may differ between older tobacco smokers and the growing population of teens taking up vaping. Vaping as an exit from tobacco smoking should still be offered to people who smoke. Once vaping is taken up, it should be promoted as a medium-term, step-down tactic (3–12 months), while ensuring that relapse to smoking is avoided. Such a strategy aligns with vaping-cessation guidance provided in the United Kingdom, Canada and New Zealand. But it's clear the landscape has shifted. Vaping is no longer just used to quit smoking; vapes are used by people who have never smoked. For some, vaping becomes a habit they want to quit in its own right, but it may not always be easy given the addictive nature of nicotine. We need dedicated support for vaping cessation to address this growing concern. Findings from our survey have been key to the development of a New Zealand vaping-cessation clinical trial currently underway. People who are interested in quitting vaping can find out more and register their interest. This article is republished from The Conversation. It was written by: Joya Kemper, University of Canterbury; Amanda Palmer, Medical University of South Carolina; Bodo Lang, Te Kunenga ki Pūrehuroa – Massey University; Chris Bullen, University of Auckland, Waipapa Taumata Rau; George Laking, University of Auckland, Waipapa Taumata Rau; Jamie Brown, UCL; Lion Shahab, UCL; Natalie Walker, Flinders University, and Vili Nosa, University of Auckland, Waipapa Taumata Rau Read more: Want to quit vaping this year? Here's what the evidence shows so far about effective strategies Young non-smokers in NZ are taking up vaping more than ever before. Here are 5 reasons why We asked young people if they wanted tighter vaping regulation to phase out nicotine – here's what they said This study was supported by a grant from the University of Auckland, Faculty of Medical and Health Sciences Research and Development Fund. Amanda Palmer has received funding from the US National Institutes of Health and Hollings Cancer Center at the Medical University of South Carolina. Bodo Lang has received funding from the Health Research Council of NZ. Chris Bullen receives funding from the Health Research Council of NZ, Ministry of Health and US NIH for research projects on smoking and vaping and personal funding from Kenvue Asia for cochairing ASEAN smoking-cessation leadership meetings. He co-chairs the smokefree expert advisory group for Health Coalition Aotearoa. George Laking has received funding from the Health Research Council of NZ. Jamie Brown has received (most recently in 2018) unrestricted funding to study smoking cessation from Pfizer and J&J, which manufacture medically licensed smoking cessation medications. Lion Shahab received personal fees from a grant funded by the US National Cancer Institute as part of his role as a member of an external scientific advisory committee outside of the submitted work. He also acted as a paid reviewer for grant awarding bodies and as a paid consultant for health-care companies and, in the past, has received honoraria for talks, an unrestricted research grant, and travel expenses to attend meetings and workshops by producers of smoking cessation medication (Pfizer/Johnson&Johnson). Natalie Walker has received personal fees from a grant funded by the US National Cancer Institute as part of her role as a member of the external scientific advisory committee. She is involved in a grant (in-kind) supported by the National Health and Medical Research Council of Australia. She also received grants from the Health Research Council of NZ and funds from the US National Institute for Health and the Food and Drug Administration tobacco regulatory science grant. She has acted as a paid reviewer for grant awarding bodies. She has no financial links with tobacco companies, e-cigarette manufacturers, or their representatives. Vili Nosa has received funding from the Health Research Council of NZ.
Los Angeles Times
21 hours ago
- Los Angeles Times
‘Lord of the Rings' director backs long-shot de-extinction plan, starring New Zealand's lost moa
WASHINGTON — Filmmaker Peter Jackson owns one of the largest private collections of bones of an extinct New Zealand bird called the moa. His fascination with the flightless ostrich-like bird has led to an unusual partnership with a biotech company known for its grand and controversial plans to bring back lost species. Last week, Colossal Biosciences announced an effort to genetically engineer living birds to resemble the extinct South Island giant moa — which stood 12 feet tall — with $15 million in funding from Jackson and his partner, Fran Walsh. The collaboration also includes the New Zealand-based Ngai Tahu Research Center. 'The movies are my day job, and the moa are my fun thing I do,' Jackson said. 'Every New Zealand schoolchild has a fascination with the moa.' Outside scientists say the idea of bringing back extinct species onto the modern landscape is likely impossible, although it may be feasible to tweak the genes of living animals to have similar physical traits. Scientists have mixed feelings on whether that will be helpful, and some worry that focusing on lost creatures could distract from protecting species that still exist. The moa had roamed New Zealand for 4,000 years until they became extinct around 600 years ago, mainly because of overhunting. A large skeleton brought to England in the 19th century, now on display at the Yorkshire Museum, prompted international interest in the long-necked bird. Unlike Colossal's work with dire wolves, the moa project is in very early stages. It started with a phone call about two years ago after Jackson heard about the company's efforts to 'de-extinct' — or create genetically similar animals to — species such as the woolly mammoth and the dire wolf. Then Jackson put Colossal in touch with experts he'd met through his own moa bone collecting. At that point, he'd amassed 300 to 400 bones, he said. In New Zealand, it's legal to buy and sell moa bones found on private lands, but not on public conservation areas — nor to export them. The first stage of the moa project will be to identify well-preserved bones from which it may be possible to extract DNA, Colossal's chief scientist, Beth Shapiro, said. Those DNA sequences will be compared with genomes of living bird species, including the ground-dwelling tinamou and emu, 'to figure out what it is that made the moa unique compared to other birds,' she said. Colossal used a similar process of comparing ancient DNA of extinct dire wolves to determine the genetic differences with gray wolves. Then scientists took blood cells from a living gray wolf and used the CRISPR gene-editing tool to modify them at 20 sites. Pups with long white hair and muscular jaws were born late last year. Working with birds presents different challenges, Shapiro said. Unlike mammals, bird embryos develop inside eggs, so the process of transferring an embryo to a surrogate will not look like mammalian IVF. 'There's lots of different scientific hurdles that need to be overcome with any species that we pick as a candidate for de-extinction,' Shapiro said. 'We are in the very early stages.' If the Colossal team succeeds in creating a tall bird with huge feet and thick pointed claws resembling the moa, there's also the pressing question of where to put it, said Duke University ecologist Stuart Pimm, who is not involved in the project. 'Can you put a species back into the wild once you've exterminated it there?' he said. 'I think it's exceedingly unlikely that they could do this in any meaningful way.' 'This will be an extremely dangerous animal,' Pimm added. The direction of the project will be shaped by Maori scholars at the University of Canterbury's Ngai Tahu Research Center. Ngai Tahu archaeologist Kyle Davis, an expert in moa bones, said the work has 'really reinvigorated the interest in examining our own traditions and mythology.' At one of the archaeological sites that Jackson and Davis visited to study moa remains, called Pyramid Valley, there are also antique rock art done by Maori people — some depicting moa before their extinction. Paul Scofield, a project advisor and senior curator of natural history at the Canterbury Museum in Christchurch, New Zealand, said he first met the 'Lord of the Rings' director when he went to his house to help him identity which of the nine known species of moa the various bones represented. 'He doesn't just collect some moa bones; he has a comprehensive collection,' Scofield said. Larson writes for the Associated Press. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
